By Fineline Cube Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo for STC007, a peripheral kappa opioid receptor (KOR) agonist, granting Salubris full rights across Greater China (Mainland China, Hong Kong, Macau, and Taiwan) for all pruritus indications—including development, regulatory filing, manufacturing, and commercialization. The non-central nervous system–penetrant molecule is designed to avoid classic opioid side effects such as respiratory depression, constipation, and addiction, offering a novel therapeutic approach for moderate-to-severe chronic itch and post-surgical pain.
Deal Structure & Territory
| Component | Detail |
|---|---|
| Licensor | Sintanovo (Chengdu, China) |
| Licensee | Salubris Pharmaceuticals |
| Asset | STC007 (peripheral KOR agonist) |
| Territory | Greater China (Mainland, HK, Macau, Taiwan) |
| Indications Covered | All pruritus-related uses (broadly defined) |
| Rights Included | Development, regulatory, manufacturing, commercialization |
The agreement excludes central-acting indications, aligning with STC007’s peripheral selectivity profile.
Drug Profile & Mechanism
- Target: Kappa opioid receptor (KOR) on peripheral sensory neurons
- Key Feature: Does not readily cross the blood-brain barrier (BBB)
- Safety Advantage: Avoids CNS-mediated adverse effects of traditional opioids:
- No respiratory depression
- No constipation
- Low abuse/addiction potential
- Therapeutic Rationale: KOR activation inhibits pruriceptive signaling and nociception at the site of injury or inflammation
This mechanism is particularly relevant in chronic kidney disease–associated pruritus (CKD-aP), a debilitating condition affecting ~40% of hemodialysis patients with limited treatment options.
Clinical Development Status
- Ongoing Trials in Mainland China:
- Phase II: Moderate-to-severe pruritus in adult hemodialysis patients with CKD
- Additional Study: Post-abdominal surgery pain management
- Primary Endpoints: Itch severity reduction (WI-NRS), rescue medication use, safety/tolerability
- Differentiation: First peripherally restricted KOR agonist in late-stage development in China for pruritus
If successful, STC007 could become the first non-immunosuppressive, non-opioid systemic therapy approved specifically for CKD-aP in Greater China.
Strategic Rationale for Salubris
- Portfolio Expansion: Complements Salubris’s existing CNS and cardiovascular franchises with a novel peripheral neuro-modulator
- High-Unmet-Need Indications: CKD-aP affects >500,000 dialysis patients in China; post-surgical pain remains undertreated due to opioid risks
- Commercial Readiness: Leverages Salubris’s established hospital sales force and regulatory expertise to accelerate launch
The deal follows Salubris’s strategy of in-licensing differentiated mechanisms from domestic innovators to de-risk R&D while capturing first-mover advantages.
Market Opportunity
- CKD-aP Market: Estimated ¥3–5 billion ($430–720M) annual value in China by 2028
- Competitive Landscape: Only difelikefalin (IV) approved globally for CKD-aP; no oral alternatives available
- Pricing Power: Novel mechanism and strong safety profile support premium reimbursement
With hemodialysis centers concentrated in urban hospitals, Salubris can achieve rapid adoption through targeted specialty detailing.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical outcomes, regulatory approval, and commercial performance. Actual results may vary due to trial data, NMPA review, and market dynamics.-Fineline Info & Tech